Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) EBT: 2018-2024

Historic EBT for Phathom Pharmaceuticals (PHAT) over the last 7 years, with Dec 2024 value amounting to -$334.3 million.

  • Phathom Pharmaceuticals' EBT rose 64.98% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.4 million, marking a year-over-year increase of 19.14%. This contributed to the annual value of -$334.3 million for FY2024, which is 65.99% down from last year.
  • According to the latest figures from FY2024, Phathom Pharmaceuticals' EBT is -$334.3 million, which was down 65.99% from -$201.4 million recorded in FY2023.
  • Phathom Pharmaceuticals' EBT's 5-year high stood at -$129.2 million during FY2020, with a 5-year trough of -$334.3 million in FY2024.
  • Moreover, its 3-year median value for EBT was -$201.4 million (2023), whereas its average is -$244.4 million.
  • Data for Phathom Pharmaceuticals' EBT shows a maximum YoY tumbled of 65.99% (in 2024) over the last 5 years.
  • Phathom Pharmaceuticals' EBT (Yearly) stood at -$129.2 million in 2020, then dropped by 9.81% to -$141.8 million in 2021, then plummeted by 39.33% to -$197.6 million in 2022, then dropped by 1.92% to -$201.4 million in 2023, then plummeted by 65.99% to -$334.3 million in 2024.